Spots Global Cancer Trial Database for capecitabine tablets
Every month we try and update this database with for capecitabine tablets cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors | NCT06208410 | Advanced Solid ... | JS105 Fulvestrant inj... Dalpiciclib Ise... Toripalimab Inj... Paclitaxel for ... Fluzoparib Caps... Pyrotinib Malea... Capecitabine Ta... | 18 Years - 75 Years | Risen (Suzhou) Pharma Tech Co., Ltd. | |
| A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer | NCT06202261 | Metastatic Brea... Recurrent Breas... Advanced Malign... | TQB2930 for inj... Paclitaxel for ... TQB3616 capsule Fulvestrant inj... Capecitabine ta... Vinorelbine tar... Eribulin mesyla... gemcitabine hyd... | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors | NCT05235542 | Advanced Malign... | AK104 AK117 Capecitabine ta... Oxaliplatin Cisplatin Paclitaxel Irinotecan Docetaxel 5-FU | 18 Years - 75 Years | Akeso | |
| Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer | NCT06255392 | Breast Cancer | Fluzoparib Apatinib Mesyla... Capecitabine ta... Vinorelbine Tar... Eribulin mesyla... Gemcitabine Hyd... Paclitaxel-albu... | 18 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Paclitaxel Polymeric Micelles for Injection Versus TPC on the Treatment of HER2-negative Metastatic Breast Cancer (MBC). | NCT06143553 | Metastatic Brea... | Paclitaxel Poly... Eribulin Mesila... Capecitabine Ta... Gemcitabine Hyd... Vinorelbine Tar... Paclitaxel (alb... | 18 Years - | Shanghai Yizhong Pharmaceutical Co., Ltd. | |
| A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer | NCT04809142 | Advanced Biliar... | TQB2450 Injecti... Anlotinib hydro... Oxaliplatin inj... Capecitabine ta... Gemcitabine hyd... | 18 Years - | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| A Bioequivalence Study of Capecitabine Tablets | NCT01846650 | Metastatic Brea... | Capecitabine ta... XELODA | 18 Years - 70 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer | NCT06255392 | Breast Cancer | Fluzoparib Apatinib Mesyla... Capecitabine ta... Vinorelbine Tar... Eribulin mesyla... Gemcitabine Hyd... Paclitaxel-albu... | 18 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease | NCT05800275 | Leptomeningeal ... Leptomeningeal ... HER2-positive M... | Tucatinib Oral ... Capecitabine ta... Trastuzumab Inj... | 18 Years - | UNICANCER | |
| Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy | NCT06268327 | Breast Cancer | Cisplatin injec... Capecitabine ta... | 18 Years - | Assiut University | |
| Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery | NCT05973864 | Triple Negative... | Pembrolizumab i... Capecitabine ta... Local radiother... | 18 Years - | UNICANCER | |
| A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer | NCT06202261 | Metastatic Brea... Recurrent Breas... Advanced Malign... | TQB2930 for inj... Paclitaxel for ... TQB3616 capsule Fulvestrant inj... Capecitabine ta... Vinorelbine tar... Eribulin mesyla... gemcitabine hyd... | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects | NCT06079983 | Breast Cancer | JSKN003 Capecitabine ta... Gemcitabine hyd... Vinorelbine tar... Paclitaxel for ... Docetaxel injec... Eribulin mesyla... | 18 Years - | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | |
| DP303c in Patients With HER2-positive Advanced Breast Cancer | NCT05901935 | HER2-positive A... | DP303c Trastuzumab Vinorelbine Tar... Capecitabine ta... | 18 Years - | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | |
| Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer | NCT04158362 | Cancer Metastat... | Paclitaxel inje... Capecitabine ta... Letrozole 2.5mg Anastrozole 1mg Fulvestrant Pre... Abemaciclib | 18 Years - | UNICANCER | |
| A Bioequivalence Study of Capecitabine Tablets | NCT01846650 | Metastatic Brea... | Capecitabine ta... XELODA | 18 Years - 70 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors | NCT06208410 | Advanced Solid ... | JS105 Fulvestrant inj... Dalpiciclib Ise... Toripalimab Inj... Paclitaxel for ... Fluzoparib Caps... Pyrotinib Malea... Capecitabine Ta... | 18 Years - 75 Years | Risen (Suzhou) Pharma Tech Co., Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
